Mounjaro 4-week results: what the before-and-after actually tells us

What's this video probably claiming?

@adoseofpaddy is doing what thousands of GLP-1 users do every week: posting a four-week side-by-side comparison showing visible body changes since starting Mounjaro (tirzepatide). The implicit claim here is that Mounjaro produced meaningful, visible fat loss in roughly 28 days. The hashtags rope in Ozempic and Wegovy, which suggests the creator is either comparing these drugs or riding search traffic from the broader GLP-1 conversation. Given the Irish hashtag context, this person is likely accessing tirzepatide through a regulated prescribing pathway in Ireland. The video probably positions Mounjaro as working fast, positions the four-week mark as a meaningful milestone, and possibly speaks to appetite suppression, energy changes, or side effects experienced along the way. None of that is inherently wrong, but the framing of a four-week result as representative of the drug's full effect is where things get complicated.

What does the science actually show?

Tirzepatide's headline trial is SURMOUNT-1 (Jastreboff et al., 2022, New England Journal of Medicine), which followed 2,539 adults with obesity over 72 weeks. At the highest dose (15mg weekly), participants lost a mean of 20.9% of body weight. That is not a four-week number. In the first four weeks, participants are typically on the starting dose of 2.5mg, which is a titration dose designed to reduce gastrointestinal side effects, not to maximise weight loss. A sub-analysis of early response data suggests most patients see 1-3% body weight reduction in the first month, with acceleration after dose escalation. Visible changes in four weeks are plausible, particularly with water weight and reduced bloating from lower food intake, but attributing this entirely to tirzepatide's pharmacological mechanism oversimplifies what is actually a months-long dose titration process. The dual GIP and GLP-1 agonism that makes tirzepatide distinct from semaglutide becomes most relevant at therapeutic doses, not at 2.5mg.

Where does the social media noise diverge from clinical reality?

Before-and-after content compresses a 72-week clinical story into a four-week show reel, and that distortion matters. First, four weeks is the titration phase. Patients on 2.5mg weekly are not yet at a dose that produces the weight loss seen in SURMOUNT-1. Second, the hashtag bundling of Mounjaro, Ozempic, and Wegovy implies these are interchangeable. They are not. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro) is a dual GIP/GLP-1 agonist. SURMOUNT-1 and SUSTAIN/STEP trials are not head-to-head comparisons of equal design. Third, visible changes at week four can reflect caloric deficit from nausea and appetite suppression rather than the drug's full metabolic effect. Viewers who see dramatic four-week results and expect the same timeline are going to be disappointed or, worse, pressure their prescribers to escalate doses faster than is safe, which increases adverse event risk considerably.

What should you actually know?

Mounjaro is a legitimate, clinically supported treatment for weight management, and patient experiences like this one have real value in reducing stigma around medical weight loss. But four weeks on a starting dose is not the story. The real story is what happens at weeks 36 to 72 at therapeutic doses, and whether patients can access consistent supply and ongoing medical supervision. In Ireland specifically, tirzepatide prescribing is subject to regulatory oversight, and access through a supervised telehealth or GP pathway is the appropriate route. Side effects including nausea, vomiting, and constipation are most common in the first four to eight weeks, and they influence early results in ways that are not always separated from the drug's actual fat-loss mechanism. If you are considering Mounjaro, a four-week TikTok result is a data point of one. SURMOUNT-1's 72-week data across over 2,500 participants is a better place to start your expectations.